1. Home
  2. CHE vs IMVT Comparison

CHE vs IMVT Comparison

Compare CHE & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CHE

Chemed Corp

HOLD

Current Price

$377.35

Market Cap

5.6B

Sector

Health Care

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$27.10

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHE
IMVT
Founded
1970
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
5.0B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
CHE
IMVT
Price
$377.35
$27.10
Analyst Decision
Buy
Buy
Analyst Count
4
9
Target Price
$498.00
$30.78
AVG Volume (30 Days)
232.8K
1.2M
Earning Date
04-23-2026
05-28-2026
Dividend Yield
0.64%
N/A
EPS Growth
N/A
N/A
EPS
18.34
N/A
Revenue
$2,529,978,000.00
N/A
Revenue This Year
$6.56
N/A
Revenue Next Year
$6.23
N/A
P/E Ratio
$20.57
N/A
Revenue Growth
4.06
N/A
52 Week Low
$365.21
$13.36
52 Week High
$593.81
$29.25

Technical Indicators

Market Signals
Indicator
CHE
IMVT
Relative Strength Index (RSI) 38.80 60.97
Support Level $365.21 $24.63
Resistance Level $398.00 $27.71
Average True Range (ATR) 8.64 1.29
MACD 2.08 0.32
Stochastic Oscillator 37.02 89.86

Price Performance

Historical Comparison
CHE
IMVT

About CHE Chemed Corp

Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: